Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the immunogenicity and safety of GSK's combined MMR vaccine in children aged four to six years has completed with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• Combined Measles-Mumps-Rubella (MMR) vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Measles-Mumps-Rubella | Phase 3 | Status: COMPLETED | Results posted: 2017-09-13